Hemab Therapeutics Holdings Inc: 5%+ holders

As of November 7, 2026, 9 holders' latest Schedule 13D or 13G filings report owning 5% or more of Hemab Therapeutics Holdings Inc. The largest reported stake is RA Capital Management, L.P.'s, at 16.6%. 10 filings are on record since May 8, 2026 (Schedule 13G, May 11, 2026).

Novo Holdings A/S also filed stake reports on 11 other companies ↓

Sell to companies like Hemab Therapeutics Holdings Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filing 2026-11-06 · Reporting person: Fmr LLC · Sole voting: 4,871,724 · Shared voting: 0 · Sole dispositive: 4,871,850 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-11-06
• Filing 2026-08-14 · Reporting person: Novo Holdings A/S · Sole voting: 4,180,550 · Shared voting: 0 · Sole dispositive: 4,180,550 · Shared dispositive: 0 · SCHEDULE 13G, 2026-08-14
• Filing 2026-08-14 · Reporting person: Avoro Capital Advisors LLC · Sole voting: 1,925,150 · Shared voting: 0 · Sole dispositive: 1,925,150 · Shared dispositive: 0 · SCHEDULE 13G, 2026-08-14
• Filing 2026-08-12 · Reporting person: Capital International Investors · Sole voting: 3,603,876 · Shared voting: 0 · Sole dispositive: 3,603,876 · Shared dispositive: 0 · SCHEDULE 13G, 2026-08-12
• Filing 2026-08-07 · Reporting person: Invus Public Equities, L.P. · Sole voting: 2,295,029 · Shared voting: 0 · Sole dispositive: 2,295,029 · Shared dispositive: 0 · SCHEDULE 13G, 2026-08-07

Hemab Therapeutics Holdings Inc has 10 Schedule 13D or 13G filings on record since 2026-05-08. 9 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind Hemab Therapeutics Holdings Inc and the warning signs.

See Hemab Therapeutics Holdings Inc's free Snapshot Watch Hemab Therapeutics Holdings Inc: email me the next time it files something

Free to see. No signup.

Keep reading

More on Hemab Therapeutics Holdings Inc and the records around it.

Hemab Therapeutics Holdings Inc elsewhere on the record

• Leadership changes Sep 2026
• Who owns it

Companies that share a holder

• Novo Holdings A/S also filed stake reports on 11 other companies: Avalyn Pharma Inc. (Aug 2026), Obsidian Therapeutics, Inc. (Aug 2026), MAPLIGHT THERAPEUTICS, INC. (Jul 2026)
• Avoro Capital Advisors LLC also filed stake reports on 18 other companies: Arrowhead Pharmaceuticals, Inc. (Aug 2026), Avalo Therapeutics, Inc. (Aug 2026), Scribe Therapeutics, Inc. (Jul 2026)
• Invus Public Equities, L.P. also filed stake reports on 24 other companies: City Therapeutics, Inc. (Oct 2026), Yarrow Bioscience, Inc. (Sep 2026), Abivax S.A. (Aug 2026)

Want the whole picture on Hemab Therapeutics Holdings Inc?

Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News

A Full Report on Hemab Therapeutics Holdings Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Hemab Therapeutics Holdings Inc covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   17 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies Hemab Therapeutics Holdings Inc by CUSIP 423494103 and gives its principal executive office as 101 MAIN STREET, SUITE 1220, CAMBRIDGE, MA 02142 (SCHEDULE 13G/A, 2026-11-06).

What the percentages are based on

See Row 11 of the cover page for each of the Filing Persons, which is incorporated herein by reference. Ownership is stated as of June 30, 2026, and the ownership percentages are based on 46,705,410 shares of common stock outstanding as of May 8, 2026, as disclosed by Hemab Therapeutics, Inc. in its Form 10-Q filed with the SEC on May 21, 2026.Sofinnova Crossover II SLP, SCHEDULE 13G, 2026-08-05

As of August 5, 2026, each of the Reporting Persons may be deemed to be the beneficial owner of the percentage of Shares listed on such Reporting Person's cover page.Raymond Debbane, SCHEDULE 13G, 2026-08-07

Purpose of Transaction (Item 4)

Ai Den-Mab LLC

The Reporting Persons who hold Common Stock directly acquired those securities as an investment in the regular course of their businesses. The Reporting Persons may engage in discussions with management, the Issuer's board of directors, other stockholders of the Issuer and other relevant parties concerning the business, operations, board composition, management, strategy and future plans of the Issuer. Subject to the terms of the Investors' Rights Agreement (as defined below), the Reporting Persons intend to re-examine their investment from time to time and, depending on prevailing market conditions, other investment opportunities, liquidity requirements or other investment considerations the Reporting Persons deem material, the Reporting Persons may from time to time acquire additional Common Stock in the open market, block trades, negotiated transactions, or otherwise and may also dispose of all or a portion of the Issuer's securities, in open market or privately negotiated transactions, and/or enter into derivative transactions with institutional counterparties with respect to the Issuer's securities, in each case, subject to limitations under applicable law. The Reporting Persons have not yet determined which, if any, of the above courses of action they may ultimately take. The Reporting Persons' future actions with regard to the Issuer are dependent on their evaluation of the factors listed above, circumstances affecting the Issuer in the future, including prospects of …The first part of Item 4 of the SCHEDULE 13D filed 2026-05-11; the filing has the rest

Timeline

Swipe the table sideways to see every column.

Questions about who owns Hemab Therapeutics Holdings Inc

Who owns Hemab Therapeutics Holdings Inc?

On this page, 9 holders' latest ownership filings report 5% or more of Hemab Therapeutics Holdings Inc: RA Capital Management, L.P. (16.6%, Schedule 13G, filed 2026-05-11), Ai Den-Mab LLC (10.4%, Schedule 13D, filed 2026-05-11), Fmr LLC (10.4%, Schedule 13G/A, filed 2026-11-06), Novo Holdings A/S (9%, Schedule 13G, filed 2026-08-14) and Deep Track Capital, LP (8.15%, Schedule 13G, filed 2026-05-08); 4 more are listed above.

Who are the largest shareholders of Hemab Therapeutics Holdings Inc?

By the share each holder's latest filing reports, the largest holders of Hemab Therapeutics Holdings Inc on this page are RA Capital Management, L.P. (16.6%), Ai Den-Mab LLC (10.4%) and Fmr LLC (10.4%).

When did RA Capital Management, L.P. buy into Hemab Therapeutics Holdings Inc?

The filings give report dates, not purchase dates. The earliest filing from RA Capital Management, L.P. on this page is the Schedule 13G, filed 2026-05-11, reporting 16.6%.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 10 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Also on the record for Hemab Therapeutics Holdings Inc

Swipe the table sideways to see every column.

Tools for this story

Each opens in a new tab, filled in for Hemab Therapeutics Holdings Inc. With no account yet, you sign up free and land on the result.

• Get an alert when Hemab Therapeutics Holdings Inc is mentioned again
• Find former Hemab Therapeutics Holdings Inc employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes